Latest / CME Outfitters Medical Education / Extraintestinal Manifestations in IBD — Screening, Referral Triggers, and Multidisciplinary Care Pathways
Transcript
- 0:01SPEAKER_02: Well, hello, I'm Amr Nayak.
- 0:03SPEAKER_02: On behalf of the CME Outfitters, I'd like to welcome you and thank you for joining us for today's podcast entitled Extraintestinal Manifestations in IBD, Inflammatory Bowel Disease, Screening, Referral Triggers, and Multidisciplinary Care Pathways.
- 0:18SPEAKER_02: Today's program is supported by an independent educational grant for Merck and Company in Railway, New Jersey, USA.
- 0:25SPEAKER_02: This activity may include discussions of products or devices that are not currently labeled for use by the U.S.
- 0:31SPEAKER_02: Food and Drug Administration, the FDA.
- 0:33SPEAKER_02: The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses, which are any uses not approved by the FDA, of products or devices.
- 0:46SPEAKER_02: So before we begin, I'd like to read our learning objectives.
- 0:50SPEAKER_02: And after listening to our podcast, important to know our learners will be able to one, identify common and high impact EIMs or extra-intestinal manifestations associated with inflammatory bile disease or IBD.
- 1:05SPEAKER_02: Two, integrate screening or EIMs using practical clinical workflows.
- 1:12SPEAKER_02: And three, coordinate multidisciplinary management for patients with IBD with systemic involvement.
- 1:19SPEAKER_02: Welcome everyone to the episode three of this Hidden Burden of IBD series.
- 1:25SPEAKER_02: And today we're talking about something that affects up to like half of all people with IBD, you know, extra intestinal manifestations.
- 1:32SPEAKER_02: Joining me are Dr.
- 1:33SPEAKER_02: Shire, Director of the IBD Center at Henry Ford Health, and Ms.
- 1:38SPEAKER_02: Orlich, a PAC with United Digestive in Atlanta.
- 1:41SPEAKER_02: Welcome to you both, guys.
- 1:43SPEAKER_02: Thanks for having us.
- 1:45SPEAKER_02: So before we get into it, um Jason, Kim, um, how often are are you guys actually seeing EIMs in your practice?
- 1:56SPEAKER_02: Do you think you're catching all of them?
- 1:59SPEAKER_00: First of all, just to call out thank you for having me and really happy to kind of represent community practice here and APPs in GI.
- 2:07SPEAKER_00: I'm gonna say on average, about 30, 35% of my IBD patients have EIMs.
- 2:13SPEAKER_00: And while I want to say I hope I catch them all, um I think all of us always have areas for improvement.
- 2:19SPEAKER_00: I think the biggest thing, I know we're gonna talk more about this, but as providers is really asking these patients about these EIMs because so many of these patients don't recognize that their non-IBD symptoms are related to their underlying IBD.
- 2:32SPEAKER_00: So again, I know we'll talk a lot about this, but so much is just being able as providers to be comfortable and confident to ask the questions to really identify these EIMs.
- 2:42SPEAKER_02: That sounds wonderful.
- 2:43SPEAKER_02: You know, I think um I think having that confidence and having that, you know, if you're not looking for it, you're not gonna find them, you know, and I think that's a big part of it.
- 2:51SPEAKER_02: Jason, do you that is that your same, is that the same experience that you've had?
- 2:55SPEAKER_01: Yeah, I I think really it just comes down to there's a lot of variance in how people even define an extra intestinal manifestation.
- 3:02SPEAKER_01: And the broader we make the definition about how IBD plays a role in other organ systems, the more likely we are to say that a person has one.
- 3:10SPEAKER_01: Um, so it really just comes down to the end of the day thinking, could this other condition be related to IBD?
- 3:17SPEAKER_01: And in turn, asking the patient because they don't always know to ask the GI doctor about something affecting a different organ system.
- 3:24SPEAKER_02: Yeah.
- 3:24SPEAKER_02: How often do you guys get multiple EIMs?
- 3:28SPEAKER_02: Is it just one or two, or sometimes you have a couple things going on?
- 3:32SPEAKER_01: I would say that uh the data says about 10% of the time, if you have one extra custom manifestation, you'll probably have another one.
- 3:38SPEAKER_01: Uh, but again, that largely reflects on how you define things.
- 3:41SPEAKER_01: So if you just stick with the big common ones like dermatologic arthritis and uh eye conditions like uveitis and iritis, about 10%.
- 3:49SPEAKER_01: And once you start expanding the definition, it probably goes up from there.
- 3:52SPEAKER_00: And I'll say in my community, I would say most of these patients have one, but I've certainly seen and it probably is around five to 10% of my practice that have more than one EIM.
- 4:02SPEAKER_02: Right.
- 4:03SPEAKER_02: And and Kim, it seems like these can kind of occur sometimes before the IBD was officially diagnosed, after, during, is that is that kind of what we're seeing?
- 4:11SPEAKER_02: Like the timing can be kind of unpredictable?
- 4:14SPEAKER_00: Yeah, it is what I see.
- 4:15SPEAKER_00: And I think that's such a important takeaway for the listeners, right?
- 4:18SPEAKER_00: And I think of a patient I saw recently who came into me for IBD, but then when I started to ask about, you know, any sort of joint pain, any skin manifestations, it was like, oh yeah, I've had this pain in my low back for three years.
- 4:31SPEAKER_00: Um, and patient had just recently started to have symptoms of IBD.
- 4:35SPEAKER_00: So I think such an important message that these EIMs can happen prior to diagnosis of IBD or after they have this diagnosis of IBD.
- 4:44SPEAKER_02: Awesome.
- 4:45SPEAKER_02: Jason, how how um how much does this affect patients?
- 4:48SPEAKER_02: You know, is it is it really impacting like quality of life, you know, healthcare utilization, work, you know, border comparison, things like that.
- 4:55SPEAKER_02: Like, does this, is this really a, you know, how much does it impact just outside like the GI symptoms?
- 5:00SPEAKER_02: Does it really interfere with both, or does it make one worse than the other?
- 5:04SPEAKER_01: I think for a lot of patients, their EIM might be the condition that they are most concerned about.
- 5:09SPEAKER_01: And it can range from pain, you know, pain is going to take you out of your day, keep you from doing the things you want to do, keep you from being the kind of person you want to be, right?
- 5:17SPEAKER_01: Um, to concerns that patients have, for instance, with some of these uh skin manifestations about long-term scarring and their concerns or fears about you know shaking hands with somebody if you have lesions on your hand, things like that.
- 5:29SPEAKER_01: So I think for the patients, um, this can be, for many cases, the most important thing about their disease, particularly when the rest of their IVD is well controlled in terms of luminal symptoms.
- 5:39SPEAKER_01: Um, obviously not all the time.
- 5:40SPEAKER_01: A lot of patients, it's the GI symptoms, but it can't be underestimated how much this affects a person's day-to-day life.
- 5:47SPEAKER_02: Gosh, yeah, it really seems to be such a bad disease, and there's so many occurrences just beyond the gut, let alone all the things that we've looked at trying to treat to target and all that.
- 5:57SPEAKER_02: This is like it seems like a whole other kind of broad aspect of this and can be pretty complex.
- 6:07SPEAKER_02: Kim, you brought up, you know, kind of a voice of the community, um, you know, at Atlanta and and across the the world in the US.
- 6:14SPEAKER_02: And, you know, I I kind of hear this from the community colleagues all the time.
- 6:17SPEAKER_02: Um they want to screen, right, for EIMs, kind of in a systematic fashion.
- 6:23SPEAKER_02: They don't know where to start.
- 6:23SPEAKER_02: People sometimes don't know where to start.
- 6:24SPEAKER_02: We're gastroenterologists, we want to treat diarrhea, just you know, GI symptoms.
- 6:28SPEAKER_02: Like, how have you incorporated this in your workflow?
- 6:31SPEAKER_02: Like, what does it look like?
- 6:32SPEAKER_02: How can we actually start doing this?
- 6:34SPEAKER_00: Yeah, so I think it's a great question.
- 6:36SPEAKER_00: I think before we start talking about how we identify patients started today, the number one is really making sure, and again, on community as community providers, that we have a really good understanding and knowledge of EIMs.
- 6:48SPEAKER_00: And again, I know we'll get into this, but kind of the most common ones, what we look like, what we want to ask patients, right?
- 6:54SPEAKER_00: So I think there's still this knowledge gap about EIMs in IBD and making sure providers understand all that.
- 7:02SPEAKER_00: Once we get through that knowledge gap, I think for me, it's really having what you said.
- 7:07SPEAKER_00: It's really the systemic, how do I fit it into that 15 or 20 minute visit that we have in community practice?
- 7:13SPEAKER_00: And we want to ask about their subjective symptoms, we want to talk about their objective markers, and then it's another thing on the list.
- 7:19SPEAKER_00: And so for me, I have a template for my IVD patients, and this is part of it.
- 7:23SPEAKER_00: So it kind of gives me that reminder to ask about any sort of joint pain, any sort of swelling, to ask about any skin changes or lesions.
- 7:31SPEAKER_00: And so I really think you need a systemic process to kind of remind those providers who aren't used to doing it to do it and make sure this becomes part of that conversation for these IVD patients we're seeing.
- 7:42SPEAKER_02: Awesome.
- 7:42SPEAKER_02: Well, that that's that sounds, I think, a templated version, I kind of guess this in there, could get someone in the right mindset of kind of figuring these things out.
- 7:50SPEAKER_02: Jason, have you um utilized like multidisciplinary kind of clinics or kind of pathways in that sense over where you're you know when you're running things at Henry Ford?
- 8:00SPEAKER_02: How are you doing this?
- 8:01SPEAKER_01: Yeah, so so to add what Kim's talking about, this is the kind of thing that whether the patient's in remission, whether they're having a flair coming to with acute symptoms, it should, a basic questionnaire should fit into the process of evaluating what's going on because it's more than just the number of bowel movements a day or blood in the stool.
- 8:19SPEAKER_01: Um so we are routinely asking during our clinic visits about your joints, about your skin, about your eyes, and it only takes about a minute to do those things.
- 8:27SPEAKER_01: When patients start flagging positive and going, well, actually these joints are a problem, actually, I get red eyes fairly frequently.
- 8:34SPEAKER_01: We lean very heavily on our peers, and I think I'm continually reminded how little I know outside of my own specialty when I get to talk with one of these physicians and hear their thoughts about how they approach the work, of how they approach the treatment, and I just go, Oh, I I thought he had red painful red eyes with painful vision.
- 8:50SPEAKER_01: I was just going to send them over there.
- 8:52SPEAKER_01: So we rely very heavily on our peers, particularly since uh when they come up with new therapies or new criteria, it's rarely passed on to us through GI articles and such until a few years later.
- 9:05SPEAKER_01: So we we really collaborate well, although we don't have a dedicated multidisciplinary clinic.
- 9:11SPEAKER_02: No, that's great.
- 9:12SPEAKER_02: I think that cross-collaboration is huge, you know, and and even even you know, can making that commit that connection in the community, just understanding that, hey, this is part of the IBD, this is part of how we want to how we want to treat our patients, I think it's I think it's fascinating.
- 9:25SPEAKER_02: You know, um, so that connection I think is really important and a big part of it.
- 9:29SPEAKER_02: So I think what Jason, you're, you're, you're saying that that connection and that ongoing care for a condition we have no cure for, I think it's is important to understand the timing of this can be throughout the process.
- 9:41SPEAKER_01: And and I would like to add, um, the same way, even though I'm a gastrinologist, I'm an IBD specialist, so I'm probably not the best person to go to for a pancreatic cyst or a complex case of a uh hepatitis, I don't think every dermatologist, rheumatologist, ophthalmologist is equally comfortable or capable to handle these things.
- 9:58SPEAKER_01: And it's very reasonable to just reach out and go, is this something you're comfortable with?
- 10:02SPEAKER_01: Do I need to refer to a specialist?
- 10:03SPEAKER_01: Um, I'm very fortunate to work with an IRITA specialist, you know, and there's not a lot out there.
- 10:08SPEAKER_01: So when you can identify that one person who wants to collaborate with you on these difficult cases, um, it becomes almost a pipeline where you can just work much more efficiently when you call up somebody who you know and you say, I have someone that needs your services.
- 10:21SPEAKER_02: Oh, that's fantastic.
- 10:22SPEAKER_02: I think finding that team, that teammate, you know, kind of in your in your peripheral peripheral network, I think, is could be huge and important in both of our scenarios, um, both for Kim and Jason and everyone here.
- 10:33SPEAKER_02: I think that's that's fantastic.
- 10:34SPEAKER_02: So these are common, right?
- 10:35SPEAKER_02: These EIMs are common.
- 10:37SPEAKER_02: Um, the impact seems very real, very real, very real world.
- 10:42SPEAKER_02: So like should we should probably just talk about like kind of what it actually looks like so that we can kind of unmask and and and all you know, kind of see where the potential gaps are, and recognition seems to be a big, a big portion.
- 10:59SPEAKER_02: Talking about two kind of frameworks is what I kind of had in mind.
- 11:03SPEAKER_02: Um, and that I think might approach how you, you know, might might change the approach of what you do.
- 11:08SPEAKER_02: And so what do you think about these two, you know, these multi-big big two frameworks in terms of things that are linked with uh the activity of inflammation in the intestines, or what we call activity linked, these EIMs, and then EIMs that may be somewhat independent from inflammatory activity in the intestines and how they occur.
- 11:29SPEAKER_02: Like how can you, Jason, take me through that?
- 11:31SPEAKER_02: Take me through what what this can can potentially look like.
- 11:34SPEAKER_01: Yeah, this is this is actually very confusing, and we know that because it's on every medical student test.
- 11:39SPEAKER_01: Is it disease associated?
- 11:40SPEAKER_01: Is it independent of disease activity?
- 11:43SPEAKER_01: When I think about extra intestinal manifestations, I think of it slightly different in terms of local and systemic.
- 11:48SPEAKER_01: And that works for both how I diagnose things, but also how I treat things.
- 11:52SPEAKER_01: So when I'm look thinking local, let's say someone comes in with a rash.
- 11:55SPEAKER_01: Well, that is a local process.
- 11:57SPEAKER_01: I want to evaluate it, I want to try to diagnose it, but then I have to think systemically, is this just the end process of another thing going on in the body?
- 12:04SPEAKER_01: And can I find other places where this is acting up?
- 12:07SPEAKER_01: So what happens is, regardless of if something is traditionally associated with disease activity or not, I want to emphasize that those are just broad categories, but they're not completely that way.
- 12:18SPEAKER_01: So for instance, erythine endosim is traditionally described as being associated with disease activity, but while that's true for most people, it's not true for every person.
- 12:27SPEAKER_01: And for instance, a central orthropathy is associated as being independent of disease activity.
- 12:31SPEAKER_01: It is the case in many cases, but it is also sometimes independent, or sorry, it is associated with active IVD.
- 12:38SPEAKER_01: So what we would do is say this person comes in, they have these EIM, if I know it's a condition associated with active disease, then I should definitely be looking for inflammation in other areas of the body that could be contributing or driving this process.
- 12:52SPEAKER_01: Conversely, if something is, for instance, um central authoropathies, but not traditionally associated with extra or sorry, with active IBD, I would still do my due diligence to rule out inflammation because I know when I send a traumatologist, the default reaction is to say, is the Crohn's ultraplatis in remission?
- 13:08SPEAKER_01: And if not, um, could you do a better job controlling that?
- 13:12SPEAKER_01: So I think every person starts with the idea of is this associated with active inflammation?
- 13:17SPEAKER_01: Should I treat it locally with you know topical therapies, with injections, et cetera, or should I be focusing on a more systemic approach by adjusting their medications like an anti-TNF or an interleukin-23 inhibitor, et cetera?
- 13:29SPEAKER_02: Interesting.
- 13:29SPEAKER_02: I like that.
- 13:30SPEAKER_02: I like that, I like that approach of local and systemic, right?
- 13:34SPEAKER_02: So sometimes, like is that do you mean like like a skin lesion might require some like topical therapy to treat that condition, and then that might that but that might unfurl that there may be something in the body going on at the same time?
- 13:46SPEAKER_02: Is that what you're kind of starting to say?
- 13:48SPEAKER_01: That'd be a perfect example.
- 13:49SPEAKER_01: So let's say somebody has something like uh pyodermic gangrinosum, which is traditionally not associated with active luminal disease from IVD.
- 13:58SPEAKER_01: Uh, this is a person that you would want to send to a dermatologist, and they'll have to discuss, they'll have to assess if we need additional diagnosis.
- 14:06SPEAKER_01: Do we need to do a biopsy of this lesion or is just the clinical presentation enough to diagnose what's going on?
- 14:11SPEAKER_01: And at the same time, we might just send off a fecal cali protectant at the same time if they're clinically intermission or a colonoscopy if they have any GI symptoms, just to make sure that an underlying case of, for instance, ultoclitis isn't driving the pyoderma to be worse than it otherwise would.
- 14:25SPEAKER_01: Um, I've had plenty of cases where pyoderma does not care what's happening with the colon, and there have been many cases where you treat what's going on with the colon and the pyoderma gets better at the same time.
- 14:33SPEAKER_02: So, Akita, it seems like there's some that some of these extra intestinal manifestations where there's a highlighted importance to make sure that the lining of the intestines aren't inflamed, and some that you may still have these inflammatory lesions, but isn't necessarily always associated with inflammation in in the intestine lining, right?
- 14:52SPEAKER_02: So, Kim, we we heard about we heard about back pain.
- 14:55SPEAKER_02: Is like tell me about your experience with back pain is terrible.
- 14:59SPEAKER_02: Tell me about back pain and IBD.
- 15:00SPEAKER_02: What does that look like?
- 15:01SPEAKER_02: What's that about?
- 15:02SPEAKER_00: Yeah.
- 15:03SPEAKER_00: And I think that's actually peripheral arthritis and this axial arthritis are the ones that I definitely see most often.
- 15:09SPEAKER_00: And when we talk about the impact of quality of life, I mean the joints, I would agree with Jason.
- 15:14SPEAKER_00: Like sometimes that is what is making them miss work and really affecting their quality of life more than their IBD.
- 15:21SPEAKER_00: So when we think about inflammatory axial back pain, we typically think about ankylosync spondylosis or a different spondylar arthropathy.
- 15:29SPEAKER_00: And what I see most often is this AS presentation.
- 15:33SPEAKER_00: And these patients typically come in, they describe this low back pain.
- 15:36SPEAKER_00: It's generally significantly worse in the morning and it improves throughout the day as they do activity.
- 15:42SPEAKER_00: It kind of starts to loosen up.
- 15:44SPEAKER_00: And as Jason had mentioned, this is one of those that unfortunately usually can be active even if we've done our due diligence and gotten their IBD under control, right?
- 15:54SPEAKER_00: And so this is where, again, having that network and that collaboration with rheumatology is so important.
- 16:00SPEAKER_00: And of course, for me also, it's thinking about what therapy are they on already?
- 16:05SPEAKER_00: Is their disease controlled, as Jason mentioned, using the biomarkers to prove that.
- 16:09SPEAKER_00: If their disease is controlled, what can we do to get that back pain under control if their disease isn't controlled?
- 16:15SPEAKER_00: Because again, that can still be the case, even though not the common one.
- 16:18SPEAKER_00: What is the therapy we're gonna do that can help their IVD get under control and that axial arthritis?
- 16:23SPEAKER_00: Because we know there's obviously certain meds and certain classes that are gonna really work to improve both that axial disease and that IBD.
- 16:31SPEAKER_00: So again, it's one of the most common ones I see, and I think it's the ones that has really the largest impact on quality of life in my patients.
- 16:38SPEAKER_02: Awesome.
- 16:39SPEAKER_02: No, that's that sounds that sounds super super clear and very important.
- 16:42SPEAKER_02: Jason, could tell me about tell me about one real patient in the last six months where like the EIM story, like you talked about, was so powerful.
- 16:50SPEAKER_02: What was what was the most important part?
- 16:51SPEAKER_02: Was it just a connection, something that you caught that could have been missed, something missed that should have been?
- 16:56SPEAKER_02: What was can you think of one thing that granular kind of kind of left you with that like liney, you know, that huge memory of it?
- 17:02SPEAKER_01: All right, I think the one, the EIM that's probably the most dramatic, usually comes back to pyoderma just because it is such an anxiety-provoking thing for the patients to see that breakdown of skin.
- 17:13SPEAKER_01: Um, so we had an ulcer of colitis patient who uh had gone through a colectomy for refractory disease.
- 17:19SPEAKER_01: They were in between stages of making a J pouch, which means that they had an ostomy in place, the colon had been removed, and they were eventually going to lose the ostomy and have a J pouch made so they could have bowel movements through the anus.
- 17:30SPEAKER_01: But around the ostomy, they started to have breakdowns of skin that got worse and worse, and eventually we diagnosed them with pyodermic gangrinosum around the stoma.
- 17:39SPEAKER_01: The first thing that we want to do is get them to the dermatologist and get them to a wound care nurse so that we can break the cycle of pathogy so that we can stop having stool leaking around the ostomy and getting to the tissue that's causing it.
- 17:51SPEAKER_01: But at the same time, we also wanted to do a colonoscopy because there was several inches of a Hartman's pouch left over because they were in between stages, and we were able to find active ultra colitis that may have been contributing to the process.
- 18:03SPEAKER_01: So, really, this was a multi-u-modality process of fixing it, where I, the gastrinologist, worked not just with a dermatologist for the pyoderma, but also for a wound care nurse to fix the underlying process that began everything.
- 18:16SPEAKER_02: No, that sounds so wonderful.
- 18:18SPEAKER_02: Sometimes it can be kind of scary and random that that something like that appears completely unrelated is has can be driven essentially even by inflammation itself.
- 18:27SPEAKER_02: Sticking, picking on the skin, or uh pun intended, Tim, like I'm gonna give you a little case here.
- 18:34SPEAKER_02: UC patient, okay, 52, comes in, bilateral, both sides, red, violaceous, violet nodules all over skins, and you're like, okay, cellulitis, he's on camping, something happened, but like that's what you're thinking.
- 18:47SPEAKER_02: Oh my God, what happened?
- 18:48SPEAKER_02: Why did you why did you talk to your doctor?
- 18:49SPEAKER_02: But is there something else that in the community, a GI clinician, an adept one like yourself, what should you be thinking?
- 18:55SPEAKER_02: How can you pick up something more there?
- 18:57SPEAKER_00: Yeah, so I'm certainly thinking about erythemodosin, right?
- 19:00SPEAKER_00: And typically these are those painful, tender red, violet nodules, typically on the anterior shins, but it doesn't always follow that rule.
- 19:07SPEAKER_00: It can be on the thigh, the arms, other places.
- 19:10SPEAKER_00: Um, often classically, bilateral, symmetrical does not have ulceration and scarring.
- 19:15SPEAKER_00: So it's definitely different than PG.
- 19:18SPEAKER_00: And it certainly can have some overlapping systemic symptoms.
- 19:20SPEAKER_00: These patients can have malaise and fevers and all those things.
- 19:24SPEAKER_00: Um, so what I think about in that case, and again, Jason mentioned like it's not always the rule, but in general, this is one of those that does parallel disease, right?
- 19:32SPEAKER_00: So I think number one in IBD is this arytheminidosum.
- 19:37SPEAKER_00: And number two, have I gotten their disease in good control?
- 19:40SPEAKER_00: Or if they're coming to me for the first time, how active is their disease?
- 19:43SPEAKER_00: We need to assess them again with biomarkers and with scopes to see the activity of the disease.
- 19:48SPEAKER_00: Typically, this is one of those that will get better as we treat the disease.
- 19:53SPEAKER_00: Um, but again, really keeping on top of mind that if there's some sort of, I always describe them to patients, they're like bruises, right?
- 19:58SPEAKER_00: And you asked Jason for his patient.
- 20:00SPEAKER_00: I was going to share a similar one that was erytheminodosum recently.
- 20:03SPEAKER_00: And it's a Crohn's patient who'd been lost to follow-up for a few years.
- 20:07SPEAKER_00: She came in to see me recently, and it was kind of like her GI tract symptoms weren't horrible.
- 20:11SPEAKER_00: The way she described was kind of on and off, alterating stools, little bit of gas, discomfort.
- 20:17SPEAKER_00: And then before I left the room, asked her about EIMs.
- 20:20SPEAKER_00: And her story was actually well, I had these painful bruises on my shins not long ago, and I went to see my primary, and they gave me a course of steroids.
- 20:29SPEAKER_00: And so such an important thing that A, asking about, but B is that, well, your disease is probably more active than we think, right?
- 20:37SPEAKER_00: It's not in remission.
- 20:38SPEAKER_00: You have this erytheminidosum explained to the patient.
- 20:41SPEAKER_00: This is often that systemic sign that there is still some inflammation there.
- 20:46SPEAKER_02: That I I really liked how you how you finished that up because sometimes symptoms and heat healing, healing and feeling has been really controversial, right?
- 20:54SPEAKER_02: And sometimes the crones don't have urgency and tenes sometimes.
- 20:58SPEAKER_02: They may just blow out on their skin, and you're like, yeah, and that made that connection, I think, is huge, right?
- 21:03SPEAKER_02: And let me just I'm building on that a little bit.
- 21:06SPEAKER_02: If I had to, if I had to give you this sentence and you had to finish it, and what how I'm gonna ask both of you guys to to kind of lean in on this.
- 21:12SPEAKER_02: The one time I wished I referred to a specialist sooner was Kim.
- 21:19SPEAKER_00: God, this is a hard one.
- 21:20SPEAKER_00: I don't know that I have like, I wish I referred sooner.
- 21:24SPEAKER_00: I'm I'm pretty uh fast to refer when needed.
- 21:28SPEAKER_00: In the case I gave you, it's almost like I wish primary would refer to us sooner instead of just giving steroids.
- 21:33SPEAKER_00: Because in this case, it's like, man, she was actually given 60 milligrams of prednisone with a significantly long taper.
- 21:40SPEAKER_00: And then she came to see me, and it's like, you know, your IBD symptoms may have even been masked.
- 21:45SPEAKER_00: I don't know if I scope enough, that's kind of hidden a lot of it.
- 21:47SPEAKER_00: So I don't have a specific one.
- 21:49SPEAKER_00: I think in general, peripheral arthritis is the ones where I do lean on rheumatology a lot.
- 21:54SPEAKER_00: You know, there are certainly some therapies we can use that aren't my go to for IBD, but that I'll use for peripheral arthropathy.
- 22:00SPEAKER_00: But I think those are the ones where sometimes I do struggle to kind of get their symptoms totally under control.
- 22:04SPEAKER_00: And I really do lean on rheumatology to help me there.
- 22:07SPEAKER_02: I love what you did there.
- 22:09SPEAKER_02: You zagged.
- 22:09SPEAKER_02: I wanted you to zag and you totally zag one.
- 22:11SPEAKER_02: I knew you'd do it.
- 22:12SPEAKER_02: I knew you'd do it.
- 22:13SPEAKER_02: But you know, but that's great.
- 22:15SPEAKER_02: If you call earlier, them calling you, you want that connection.
- 22:18SPEAKER_02: It's got to be both ways, right?
- 22:19SPEAKER_02: So I actually did Jason about the same thing.
- 22:21SPEAKER_02: Once I might refer to a specialist sooner or a scenario, something else.
- 22:25SPEAKER_01: Unfortunately, I have so many of these because uh one of our friends, we he's a peer who worked with us.
- 22:32SPEAKER_01: He works in New Jersey now.
- 22:33SPEAKER_01: He used to be a fellow, and he told us that he had a sibling with ankylotine spondylitis.
- 22:38SPEAKER_01: And when this gentleman as a fellow came into my clinic, he proceeded to find ankylisting spondylitis all over my patients.
- 22:45SPEAKER_01: And then I was left with the idea that I had been practicing for several years and probably missed dozens and dozens of patients with that EIM.
- 22:52SPEAKER_01: So I would just say, in general, um, while I hear about things like SI joint inflammation, just broadening my thought process of what an EIM is and what my patients have.
- 23:01SPEAKER_01: And it just reminded me so many times of like, I need to ask more questions when patients come in.
- 23:07SPEAKER_01: So, Dr.
- 23:07SPEAKER_01: Peric, shout out to you.
- 23:09SPEAKER_02: All right, excellent, excellent.
- 23:10SPEAKER_02: Well, you know, you guys are both wildcards and ZAG.
- 23:13SPEAKER_02: And I think let's let's table this and remember, let's remember that that's that spondylarotrophy, that axial spondylarotropathy, that back pain, that central axial arthropathy.
- 23:22SPEAKER_02: We don't have a lot for it right now.
- 23:24SPEAKER_02: We have other things, but I think that we we really it's an it's an area where we can do a lot of benefit for our patients.
- 23:30SPEAKER_02: And I think it's everywhere, right?
- 23:33SPEAKER_02: Um, you know, the pain, the back pain, pain in your back, pain in pain, the pain in the bottom, it's it's all linked.
- 23:38SPEAKER_03: And I want to remember that we're gonna come back to that in a little bit here.
- 23:47SPEAKER_03: So I think we know now what to look for.
- 23:49SPEAKER_02: I mean, I think that was a great story about how unmasking certain things, until you see them and bring it to the to the forefront, we don't know where that's there.
- 23:56SPEAKER_02: So, how do we we want to kind of want to transition to how do we build this?
- 23:59SPEAKER_02: How do we change what we're doing on a day-to-day, how do we build that into our practice?
- 24:03SPEAKER_02: Because recognition about the workflow is one thing, but then the implementation, right?
- 24:07SPEAKER_02: It's almost like any ideas can potentially be successful.
- 24:10SPEAKER_02: How do you put A to B and put put um get get things moving, right?
- 24:14SPEAKER_02: So I want to go before we go any further, let's let's both you guys lean in on knowing when to refer and how urgently, you know.
- 24:22SPEAKER_02: So, you know, we talk about we talk about bowel urgency all the time, but in terms of urgency and when we can wait, when we can come in, let's let's pivot a little bit on that.
- 24:29SPEAKER_02: And so let I want to everyone to feel confident about like certain triggers that you have in your mind inside you can impart these nuggets to everybody else and and and and that.
- 24:37SPEAKER_02: So, Kim, Kim, what are what are some of your like triggers to be like, okay, we need to get you in right now, you know, within a week, or like, hey, you can see some of the next month.
- 24:46SPEAKER_02: Like, how does that yeah?
- 24:48SPEAKER_00: So, you know, the ones that I think about of urgent uveitis is a big one.
- 24:51SPEAKER_00: So if a patient comes in with IBD and they have eye pain, they have photophobia, they have any vision changes, blurriness to their eyes, this is of course the one that it's like we need to go get you seen now, worrying about the complications of that.
- 25:04SPEAKER_00: I don't see as much of pyoderma, but that is also something that when I see it, that is uh I need help now from referring, um, versus those patients where ankylosing has such an impact, you know, it's not something I need the patient seeing today, right?
- 25:18SPEAKER_00: And I think the biggest message Jason got to share, he's not part of a multidisciplinary team, but he's still part of an academic center.
- 25:24SPEAKER_00: I think being in the community, one of the things I want to make sure the listeners really um have comfort with is developing your own network, right?
- 25:33SPEAKER_00: Because we really have to build that on our own.
- 25:36SPEAKER_00: And when it comes to these referrals, whether it's urgent, whether it's not as urgent, we can't refer unless we know who to refer to.
- 25:43SPEAKER_00: And I think Jason really honed in on it's not just having a dermatologist, it's having a dermatologist who's comfortable with IBD.
- 25:49SPEAKER_00: And so I'll share being in the community and going on almost 17 years of practicing in GI in the community.
- 25:55SPEAKER_00: It's just so important that we network and we build our own care team if we're not part of a multidisciplinary team.
- 26:01SPEAKER_00: And then when we're able to have these patients who need that urgent referral, we're able to reach out to somebody automatically get them in so that they really can get seen stat when we need it.
- 26:11SPEAKER_00: So to me, it's kind of like having colorectal surgery.
- 26:13SPEAKER_00: All of us who treat IBD, we need to have a colorectal surgeon in our back pocket that we're really comfortable with.
- 26:18SPEAKER_00: And this is really the biggest thing is go to local networking events, go to IBD events, make sure that you meet those colleagues who are part of your network that are really comfortable with IBD and make EIMs of IBD.
- 26:28SPEAKER_00: Um, but again, going back, I think about those urgent things as the patients who really it's affecting their quality of life.
- 26:34SPEAKER_00: It's so severe, or again, the patients with like uveitis that we need to get them in now.
- 26:38SPEAKER_02: Okay.
- 26:39SPEAKER_02: So Jason, for your for patients, patients for you for for joint pain.
- 26:45SPEAKER_02: You you just gave a beautiful story about the ankylosing spondylitis and how that kind of came up.
- 26:50SPEAKER_02: Did you change something?
- 26:52SPEAKER_02: Like did you did you specifically tell patients one thing and explain it to them and something that really kind of kind of worked?
- 26:58SPEAKER_02: Did you develop that kind of aspect of it?
- 27:00SPEAKER_01: Well, I think it's just being more thorough in how you ask questions.
- 27:03SPEAKER_01: Um, you know, again, screening for EIMs doesn't take but a minute in your clinic.
- 27:08SPEAKER_01: And when you get answers like no, um, you can move on to the next things.
- 27:11SPEAKER_01: But I think when you start talking about these, uh, for instance, arthritis for instance central arthrophysis, asking more questions, you know, at what time of day is the stiffness?
- 27:21SPEAKER_01: Uh, does it affect your range of motion?
- 27:23SPEAKER_01: Um, what kind of things make the pain worse, et cetera?
- 27:26SPEAKER_01: And I think that as you as you experiment more with asking the questions, you become a little bit more comfortable in it.
- 27:31SPEAKER_01: I don't think any of us in GI are inherently comfortable with the idea of asking joint problems, eye problems, kidney problems, et cetera.
- 27:39SPEAKER_01: But I think that once we practice it a little bit, we go, you know what, I'm more comfortable with the answers that I'm getting.
- 27:43SPEAKER_01: And then just being okay with the idea that I don't have all the answers, that sometimes if someone tells me about a problem that they have, I can send it to a rheumatologist and they'll say, well, it's not A, but it is something else that we're gonna go work up.
- 27:54SPEAKER_01: And you go, that's good enough.
- 27:55SPEAKER_01: I think the patient just wants to be with somebody who knows what's going on.
- 27:58SPEAKER_02: All right.
- 27:58SPEAKER_02: So I heard it.
- 27:59SPEAKER_02: I heard it.
- 28:00SPEAKER_02: I think the trigger for everyone now moving forward is gonna be just give me a minute.
- 28:03SPEAKER_02: Give me one minute here, give me one minute, and that's when the EIM, the minute for the EIMs comes in.
- 28:08SPEAKER_02: I love it.
- 28:09SPEAKER_02: It's fantastic.
- 28:10SPEAKER_02: Um, I'm gonna I'm gonna I'm gonna have a little clinical scenario for you, okay, Jason?
- 28:15SPEAKER_02: Um you've seen this.
- 28:16SPEAKER_02: I'm just gonna kind of bring it out there.
- 28:18SPEAKER_02: Patients switch from adolemimab to vetalismab, vetalismab, depending on which which can't be laid in that pronunciation, but let's call it vitalismab.
- 28:29SPEAKER_02: Two months later, new joint pain, rheumatologist says, hey, it's the new drug.
- 28:34SPEAKER_02: What do you tell that referring physician?
- 28:36SPEAKER_02: How do you handle this?
- 28:37SPEAKER_02: What do you do?
- 28:39SPEAKER_01: So the challenge I get is that sometimes patients get better in spite of what we do for them, right?
- 28:45SPEAKER_01: And I am very focused on the bowel because that's what I diagnose, and I'm very focused on the immune system because that's what I treat.
- 28:53SPEAKER_01: Um, but sometimes we are treating things unintentionally.
- 28:56SPEAKER_01: Sometimes patients come in and I put them on a medication and I am treating their Crohn's, but the medication also treats rheumatoid arthritis, ankylocene spondylitis, a half a dozen other things.
- 29:08SPEAKER_01: And then when we switch from medication A to medication B, we find out that the patient has had that other condition for months or years, but we were already treating it.
- 29:17SPEAKER_01: And the new medication doesn't necessarily treat the same mechanism of action, so it doesn't necessarily get you the same benefits.
- 29:23SPEAKER_01: Um, so a lot of patients get frustrated.
- 29:25SPEAKER_01: A lot of patients and physicians are confused as to why the new medication is causing the problem.
- 29:29SPEAKER_01: But the answer is you've just unmasked that your patient has two separate conditions, and it could be a separate distinct rheumatological condition, or it could be an extra intestinal manifestation that the new medication doesn't treat.
- 29:40SPEAKER_02: Wow, I like that.
- 29:41SPEAKER_02: I like that unmasking.
- 29:42SPEAKER_02: So this is more Jim Carrey with the mask or the man in the iron mask, uh, you know, kind of with the DiCaprio.
- 29:48SPEAKER_02: So what lies beneath may be something big.
- 29:50SPEAKER_02: I think this is huge because, you know, for years we just had one mechanism of action.
- 29:55SPEAKER_02: We have like three or four now, but I think we're gonna have like 10 or 12 soon.
- 29:59SPEAKER_02: Let's just be like overly cautiously optimistic.
- 30:02SPEAKER_02: And I think this is gonna occur so much more.
- 30:04SPEAKER_02: And that that gets me on something, you know, um, this anti-TNF, what you talk about, masking effect, you know, this man of the iron mask or this mask where you put it on and something looks like it hasn't potentially there.
- 30:15SPEAKER_02: This is there.
- 30:16SPEAKER_02: This is a lot.
- 30:17SPEAKER_02: We kind of want to walk through what this looks like, you know, um, in your practice.
- 30:21SPEAKER_02: Like, do you, you know, have had, you know, do you kind of keep an eye out for this when you're thinking on transitioning therapies?
- 30:27SPEAKER_02: What do you do?
- 30:28SPEAKER_01: So a lot of this is just collaboration with our peers, right?
- 30:31SPEAKER_01: So if I know that I'm going to switch a medication, I'm often asking about EIMs as a way to figure out what I can be finding two birds, one stone situations for, or other comorbid conditions, right?
- 30:43SPEAKER_01: So an example is if your patient has multiple sclerosis and ulcerclitis, can you use an ozanamide product?
- 30:49SPEAKER_01: The question is if your patient has psoriasis and Crohn's, can you use an endequin-23 inhibitor?
- 30:53SPEAKER_01: So a lot of this is about just recognizing that at the end of the day, most of our patients do not like being on medications.
- 31:01SPEAKER_01: They do not want to be on more medications.
- 31:02SPEAKER_01: And if I can find a way to reduce the medication burden by finding one medication that treats multiple conditions, they generally are happier if we do that.
- 31:11SPEAKER_02: Right.
- 31:11SPEAKER_02: So I think it's kind of kind of pivoting away from that instinct, right, to blame the drug and putting the focus back in the disease and managing the condition really well, right?
- 31:19SPEAKER_02: And so how Kim, Kim, how do you how are you doing this?
- 31:23SPEAKER_02: Like how are you seeing this recognized and in your your experience with this in the community?
- 31:28SPEAKER_00: Yeah, I mean, just like Jason said, I mean, I've certainly seen it, right?
- 31:31SPEAKER_00: We stopped TNF for whatever reason, loss of response, not responding, sorry, uh psoriasis, you know, side effect from TNF, anything that happens.
- 31:41SPEAKER_00: Um, I think it's hard to predict, right?
- 31:43SPEAKER_00: And so we're gonna choose the next medicine that's best for the patient if they had an EIM that was being masked or just put into remission because of the therapy they were on.
- 31:53SPEAKER_00: It really, again, to me, comes to asking those patients the question.
- 31:56SPEAKER_00: So we're gonna decide what their therapy to put them on next based on their overall picture.
- 32:01SPEAKER_00: And then when they come in to see us and we follow up on their subjective, objective IBD, again, ask the questions, right?
- 32:07SPEAKER_00: Now are they having joint pains?
- 32:09SPEAKER_00: Now have there been any other new, you know, lesions or anything of that sort.
- 32:13SPEAKER_00: So certainly seen it.
- 32:14SPEAKER_00: And I think it's on us to really become the detective of is this just an EIM that was masked, was treated by the drug, or is this really an arthralgia from a new therapy that we've put them on, which obviously still can happen with some of our therapies?
- 32:27SPEAKER_02: Great.
- 32:27SPEAKER_02: No, so what I'm hearing there is timing.
- 32:29SPEAKER_02: Don't just because they people may not have had something before, just keep kind of going through your give me one minute with Jason, right?
- 32:36SPEAKER_00: I mean, this is something I think we should ask about every time.
- 32:39SPEAKER_00: I mean, we owe it to our patients.
- 32:40SPEAKER_00: Has there been any new right?
- 32:41SPEAKER_00: We're asking them about bleeding every time.
- 32:43SPEAKER_00: We're asking about their stools, we're asking about their pain.
- 32:45SPEAKER_00: This should just be a have you had any new or change in joint pains?
- 32:50SPEAKER_00: Have you had any new rashes or lesions or redness in your eyes or blurry vision, right?
- 32:55SPEAKER_00: And as Jason mentioned, I agree, it really just takes a minute.
- 32:58SPEAKER_00: Um, I think the part that's hard is we need to be prepared if the answer is yes, what we're gonna do, who we're gonna refer to, what our therapy is gonna be.
- 33:08SPEAKER_00: So the providers really need to be comfortable with that part too.
- 33:11SPEAKER_02: Okay.
- 33:12SPEAKER_02: All right, guys, finish this sentence for me.
- 33:14SPEAKER_02: The biggest mistake I see community GI clinicians make with EIMs.
- 33:18SPEAKER_02: Let's just say any GI clinician.
- 33:19SPEAKER_02: So let's not pick on the community, right?
- 33:20SPEAKER_02: We're all part of the same community, right?
- 33:22SPEAKER_02: We're all taking care of IBD patients.
- 33:23SPEAKER_02: So what's the one biggest mistake?
- 33:25SPEAKER_02: Kim?
- 33:26SPEAKER_00: Oh, I have two.
- 33:27SPEAKER_00: Not asking about them and then not knowing how to treat them.
- 33:31SPEAKER_00: So to Jason's point, like a patient wants one medicine.
- 33:33SPEAKER_00: If there's one that can treat both, that's what our patient wants and deserves.
- 33:37SPEAKER_00: And so I think it's it's not asking about EIMs, and then it's not knowing the therapies that will treat the EIMs in the IBD.
- 33:45SPEAKER_00: Connecting the dots.
- 33:46SPEAKER_02: Okay, oh, like connecting the dots.
- 33:48SPEAKER_02: Okay, Jason.
- 33:49SPEAKER_01: To build on what Kim said, I would just say the next thing I would add is thinking locally and or not thinking locally and systemically, just looking at the local problem and saying this is the only problem and not realizing that it connects to a bigger picture of what's happening with the patient's immune system at that time.
- 34:04SPEAKER_02: Okay.
- 34:05SPEAKER_02: Jason, lay it on us.
- 34:06SPEAKER_02: The single most important thing about EIMs that community GIs either don't know or don't act on.
- 34:13SPEAKER_01: Again, I don't I don't want to say anything about community GIs.
- 34:15SPEAKER_01: I just think the single big thing that people don't know or don't act on is that uh our patients are traveling all over the state, going to other physicians, other specialties, ERs being diagnosed and treated with conditions that are actually under the umbrella of what we can help them with.
- 34:30SPEAKER_01: So just looking through the medical records, seeing what they've been up with up to since the last time we saw them can really help a lot of these patients feel better.
- 34:37SPEAKER_02: Okay.
- 34:38SPEAKER_02: Kim?
- 34:39SPEAKER_00: Yeah.
- 34:40SPEAKER_00: I I mean we really have talked about this, but I'm gonna summarize what we talked about.
- 34:43SPEAKER_00: IBD is not just a disease of the GI tract.
- 34:46SPEAKER_00: So it's a disease of the immune system.
- 34:48SPEAKER_00: It is systemic, as Jason said.
- 34:49SPEAKER_00: It can affect the entire body.
- 34:51SPEAKER_00: Inflammation can be in other places, even when it's not in the gut.
- 34:55SPEAKER_00: Um, and I heard this from somebody, I'm gonna share this.
- 34:57SPEAKER_00: I hope it helps somebody listening.
- 34:59SPEAKER_00: I love the analogy.
- 35:00SPEAKER_00: IBD is like a fire, and these EIMs can be like the sparks, right?
- 35:04SPEAKER_00: And so we want to put out the fire, but the sparks can still be there, and we need to make sure that we understand both.
- 35:11SPEAKER_00: And again, the systemic impact of this disease.
- 35:14SPEAKER_02: I like it.
- 35:15SPEAKER_02: I like it.
- 35:15SPEAKER_02: I I I'm I'm I'm imagining Dragons fan.
- 35:18SPEAKER_02: So I was listening, I was thinking of the song that deep from my bones, straight from inside, I'm waking up, it's coming in from my bones, throw radioactive, right?
- 35:26SPEAKER_02: So it's it's there.
- 35:26SPEAKER_02: So if you could tell one IBD, finish the sentence, if you could tell one IBD patient one thing about their joints, skin, and eyes, it would be.
- 35:36SPEAKER_01: I would say um bring them up with your GI doctor and always ask who's be related to my IBD before we assume it's not.
- 35:43SPEAKER_02: Okay, I like it.
- 35:44SPEAKER_02: I like it.
- 35:44SPEAKER_02: I think I think we should kind of get into this.
- 35:47SPEAKER_02: I want to get into you guys, put you on the spot because you guys are awesome.
- 35:50SPEAKER_02: Rapid fire.
- 35:51SPEAKER_02: All right, rapid fire.
- 35:52SPEAKER_02: Tell me with first instinct, you know, no explanation, just give them what your first kind of thing is.
- 35:57SPEAKER_02: We'll start starting with the top, okay?
- 35:59SPEAKER_02: Kim, you ready?
- 36:00SPEAKER_00: Ready.
- 36:01SPEAKER_02: Okay.
- 36:01SPEAKER_02: Eye redness in an IBD patient, same day or routine referral?
- 36:06SPEAKER_00: Uh, if isolated, painless redness, regular referral.
- 36:12SPEAKER_00: Again, if I'm worried about uveitis, urgent.
- 36:15SPEAKER_02: Okay.
- 36:16SPEAKER_02: Jason, erythemonodosum, EN in a 55-year-old UC patient.
- 36:21SPEAKER_01: Uh, this is gonna be an urgent referral, but I'm gonna start treating the IBD itself.
- 36:26SPEAKER_02: I like it.
- 36:27SPEAKER_02: I like it.
- 36:27SPEAKER_02: Kim, 44-year-old man with Crohn's disease, gut and endoscopic recommission on veto lysimab, worsening back pain, recurrent eye redness, escalate that IBD therapy or call a specialist.
- 36:38SPEAKER_00: I mean, I'm definitely gonna loop in a specialist here, knowing that they're in remission.
- 36:43SPEAKER_02: Yes.
- 36:44SPEAKER_02: Excellent, excellent.
- 36:46SPEAKER_02: And then we, Jason, you talked about PG and stoma wounds.
- 36:49SPEAKER_02: So, you know, that's a that's a that's a debride or don't.
- 36:51SPEAKER_02: Debreed, did I say that wrong?
- 36:53SPEAKER_02: Debreed or don't?
- 36:54SPEAKER_01: Uh the answer is, oh God, no.
- 36:56SPEAKER_01: Uh defining feature of pyoderma is pathergy.
- 36:59SPEAKER_01: And so I would say as a general principle, do not debride a biopsy to help you diagnose and find the right path by a trained dermatologist is absolutely appropriate, but I should not be mucking around making the lesion worse.
- 37:13SPEAKER_02: Kim, etanacts for a patient with IBD and axial spondylar property.
- 37:18SPEAKER_02: I made you the back pain leader.
- 37:20SPEAKER_00: We are not going to use that, first of all, not effective in IBD.
- 37:25SPEAKER_00: Um, number one, that it can actually worsen IBD.
- 37:28SPEAKER_00: So no.
- 37:29SPEAKER_02: Okay.
- 37:30SPEAKER_02: Topical steroids for episcleritis, Jason?
- 37:34SPEAKER_01: Well, that is one of the therapies.
- 37:35SPEAKER_01: I don't think that's the first therapy.
- 37:37SPEAKER_01: And admittedly, it's not something I would prescribe.
- 37:39SPEAKER_01: That would come from an ophthalmologist.
- 37:41SPEAKER_01: But I think we start with NSAIDs and lubrication.
- 37:44SPEAKER_02: All right.
- 37:45SPEAKER_02: I like it.
- 37:45SPEAKER_02: I like it.
- 37:47SPEAKER_02: Guys, um I kind of wanted to take take take me, give can you give me one word?
- 37:53SPEAKER_02: Right?
- 37:54SPEAKER_02: Just give me one word.
- 37:55SPEAKER_02: This is this is super hard, so I like this.
- 37:57SPEAKER_02: One word only.
- 37:58SPEAKER_02: Describe why EIM care coordination fails in practice.
- 38:05SPEAKER_00: I'm gonna go with fragmented.
- 38:07SPEAKER_02: Ah, I like that.
- 38:09SPEAKER_01: Fragmented.
- 38:10SPEAKER_01: Okay.
- 38:11SPEAKER_01: Jason, I I'm jealous because I can't come up with a word, a single word that defines what it is.
- 38:16SPEAKER_01: Um, I mean, I want to use the word unaware, and I think it just everyone, the patient is unaware that the GA doctor can help.
- 38:23SPEAKER_01: The GA doctor is unaware of what the patient is going through.
- 38:26SPEAKER_01: Excellent, excellent.
- 38:27SPEAKER_02: I I like that.
- 38:28SPEAKER_02: Fragmented and aware and awareness, right?
- 38:31SPEAKER_02: Unawareness.
- 38:32SPEAKER_02: I like that.
- 38:32SPEAKER_02: Those are those are just things that'll that are that kind of kind of really impact our day-to-day practice everywhere and things that we can improve in IBD and in healthcare in general.
- 38:47SPEAKER_02: We've spent, you know, today kind of talking about IBD as a systemic disease.
- 38:53SPEAKER_02: And um we talked about the mechanisms of action and unmasking and cool things, but uh I and talk about new therapies that are coming up, and the science really is starting to catch up, right, to the fact that IBD is systemic, complex, and the manifestations can be so different in everybody.
- 39:09SPEAKER_02: Everyone's IBD is different.
- 39:10SPEAKER_02: And so TL1A really seems to be appears to be a cytokine that appears to operate across gut, joints, skin, eye, you know, all of those areas, these same axes that we've been kind of discussing today.
- 39:25SPEAKER_02: And it also drives fibrosis, which we haven't gotten to here too much.
- 39:29SPEAKER_02: And an agent potentially targeting TL1A could could address intestinal disease, theoretically, right?
- 39:35SPEAKER_02: And I think and and and systemic complications that really could be quite transformative.
- 39:41SPEAKER_02: So Tulisicobart, Tulisicibart, uh apologize, is one of these such agents currently in phase three.
- 39:49SPEAKER_02: You know, Jason, Kim, what kind of mechanism um Ian for for where EIM management is heading?
- 39:56SPEAKER_02: What kind of what kind of mechanism do you think this could potentially be where management's kind of kind of bridging everything together?
- 40:02SPEAKER_02: You talked about one therapy, the patients don't like kind of going one way.
- 40:06SPEAKER_02: They like a simple solution to a complex problem.
- 40:09SPEAKER_02: What do you think?
- 40:11SPEAKER_00: I mean, I think it's exciting, right?
- 40:12SPEAKER_00: You summarized it.
- 40:13SPEAKER_00: It means that we may have the potential to have an agent that treats both the intestinal inflammation and multiple EIMs through a single mechanism.
- 40:23SPEAKER_00: So while it's still under investigation, I think it's a super promising step towards this kind of more unified approach to managing the whole systemic spectrum of IBD.
- 40:37SPEAKER_01: Yeah, I would say that I am cautiously hopeful.
- 40:41SPEAKER_01: And it just comes back to I view IBD, people who care for patients with IBD, as we're like Batman, right?
- 40:48SPEAKER_01: We have a utility belt, we have all of our toys and tools, and we hope we have the right thing for the occasion, but I oftentimes we just take whatever we can get and make it work in the situation.
- 40:57SPEAKER_01: So it would be nice to have something that is designed to help us.
- 41:00SPEAKER_01: That said, I will always have a degree of caution with something that is only in the phase three of testing because I've seen things get very far and not end up coming to market.
- 41:08SPEAKER_01: So while I am hopeful and optimistic, um, it's not something that I am recommending or telling my patients about yet.
- 41:15SPEAKER_02: No, that's a great point.
- 41:16SPEAKER_02: And I think caution to doing the science, investigating things, is it safe?
- 41:21SPEAKER_02: Does it work?
- 41:21SPEAKER_02: I think that's that's of utmost importance.
- 41:24SPEAKER_02: And I think the one thing that that you guys can we can we can kind of agree on, I think, is is really making sure care coordination is optimized.
- 41:32SPEAKER_02: So if you had to leave leave this, leave us with um one big kind of important kind of message for extra intestinal manifestation coordination.
- 41:43SPEAKER_02: Um it doesn't have to be complicated.
- 41:45SPEAKER_02: We talked about a lot of things, but it only requires what, Kim?
- 41:49SPEAKER_02: What what what is the simple sauce?
- 41:51SPEAKER_02: What's your what's your secret?
- 41:52SPEAKER_00: Again, I don't think it's a secret.
- 41:54SPEAKER_00: I think it's just asking the questions and building your network.
- 41:57SPEAKER_02: I like it.
- 41:58SPEAKER_02: Building a network, looking for them, right?
- 42:00SPEAKER_00: Looking for it, asking for them, and knowing who and when to refer to.
- 42:04SPEAKER_02: Okay.
- 42:05SPEAKER_01: Jason?
- 42:06SPEAKER_01: I want to copy Kim's answer again.
- 42:08SPEAKER_01: She nailed it.
- 42:09SPEAKER_01: I mean, the the right answer is like everything in medicine, it just comes down to taking the time to ask.
- 42:15SPEAKER_01: And then if you ask and you don't know the answer, asking someone else for help.
- 42:19SPEAKER_02: I like that.
- 42:20SPEAKER_02: When to know when to ask for help and rely on your teammates, right?
- 42:23SPEAKER_02: Um doing everything on your own.
- 42:25SPEAKER_02: So I think it it takes a village to really help help our patients and have a variety of characters there.
- 42:30SPEAKER_02: So um so I wanted to thank you guys definitely um for for talking and chatting, chatting all together.
- 42:39SPEAKER_02: Um, to our learners, you know, EIMs are not a niche, right?
- 42:43SPEAKER_02: They are a part of IBD care, routine IBD care.
- 42:48SPEAKER_02: If you take one thing from today, you know, let it be this, screen at every visit, like Kim said, know when to refer, and don't switch the biologic before you call a specialist.
- 42:59SPEAKER_02: So recognize early, screen consistently, and and and you know, treat thoughtfully, right?
- 43:06SPEAKER_02: So this is part of our big objectives in the beginning.
- 43:09SPEAKER_02: Identify, integrate, right?
- 43:11SPEAKER_02: And coordinate.
- 43:12SPEAKER_02: I like that.
- 43:13SPEAKER_02: Identify, integrate, and coordinate.
- 43:15SPEAKER_02: Um, and so I think that's really important that we continue to um continue to emphasize that and do great things for our patients.
- 43:22SPEAKER_02: So, and with that, I'll share with you a few smart goals that you can implement to put information into action when you get back into your practice, right?
- 43:29SPEAKER_02: So try to increase the percentage of people with IBD who are screened for EIMs at every clinic visit using a standardized intake prompt, improve documentation of active EIMs as a separate diagnosis on the problem list for people with IBD, and ensure that patients with IBD who develop new systemic symptoms after a biologic switch receive specialty consultation prior to any therapy change.
- 43:58SPEAKER_02: Think, think and think.
- 43:59SPEAKER_02: So we have some additional goals for increased professional communication and collaboration as well.
- 44:04SPEAKER_02: And they include establishing clear communication channels, commitment to evidence-based practices, right, Jason, and expressing respect for other healthcare professionals' knowledge and contribution.
- 44:18SPEAKER_02: So assessing collaboration, competency, and also in a willingness to accept feedback from other healthcare practitioners.
- 44:25SPEAKER_02: Also making sure patient and caregiver values, preferences, and needs are considered by all healthcare professionals.
- 44:31SPEAKER_02: And again, most importantly, that framework identifying having a framework for a structured communication pattern.
- 44:39SPEAKER_02: So for additional resources, visit www.cmeoutfitters.com, www.cmeoutfitters.com for clinical information and certified educational activities and a virtual education hub.
- 44:54SPEAKER_02: Importantly, to receive CME or CE credit for this activity, participants must complete the post test and evaluation online.
- 45:01SPEAKER_02: Participants will be able to download and print their certificate immediately upon completion.
- 45:06SPEAKER_02: And remember, this is the third of a three-part podcast series on IBD.
- 45:10SPEAKER_02: I'm also hosting two additional episodes Beyond Symptoms, such as the hidden burden of IBD and the future of disease modification, as well as fibrosis in IBD, pathogenesis, risk stratification, and objective monitoring.
- 45:24SPEAKER_02: And I really hope you'll be able to join us.
- 45:27SPEAKER_02: Thank you, and we'll see you next time.